HER2基因在唾液腺恶性多形性腺瘤细胞增殖、周期、凋亡中的作用

doi:10.19438/j.cjoms.2018.04.004

中国口腔颌面外科杂志 ›› 2018, Vol. 16 ›› Issue (4): 310-316.doi: 10.19438/j.cjoms.2018.04.004

HER2基因在唾液腺恶性多形性腺瘤细胞增殖、周期、凋亡中的作用

夏亮^1,2,*, 汪洋^1,*, 胡宇华¹, 王丽珍¹, 顾挺¹, 李江¹, 田臻¹

1.上海交通大学医学院附属第九人民医院·口腔医学院口腔病理科,
2.口腔颅颌面科,国家口腔疾病临床研究中心,上海市口腔医学重点实验室,上海市口腔医学研究所,上海 200011

收稿日期:2017-10-16 修回日期:2017-12-25 出版日期:2018-07-20 发布日期:2018-08-09
通讯作者: 田臻,E-mail：tian0304_cn@163.com
作者简介:夏亮（1990-）,男,E-mail：anglexialiang@126.com;汪洋（1989-）,男,E-mail：cmfuyangwang@126.com。
基金资助:
国家自然科学基金（81272976,81372910）

Effect of HER2 gene on cell proliferation, cell cycle and apoptosis in salivary malignant pleomorphic adenoma

XIA Liang^1,2, WANG Yang¹, HU Yu-hua¹, WANG Li-zhen¹, GU Ting¹, LI Jiang¹, TIAN Zhen¹

1.Department of Oral Pathology,
2.Department of Oral and Craniomaxillofacial Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology. Shanghai 200011, China;

Received:2017-10-16 Revised:2017-12-25 Online:2018-07-20 Published:2018-08-09

摘要/Abstract

摘要： 目的:通过体外抑制唾液腺恶性多形性腺瘤（malignant pleomorphic adenoma,MPA）中人表皮生长因子受体2（Human epithelial growth factor receptor 2,HER2）,分析其与肿瘤细胞增殖、周期和凋亡等恶性生物学行为的相关性,以期评估其作为靶向治疗位点的可能性。方法:检测MPA细胞系中HER2蛋白表达及基因扩增情况,应用靶向抑制剂处理肿瘤细胞,检测肿瘤增殖、周期、凋亡等生物学行为的改变,HER2蛋白表达改变及其对下游通路的影响。采用SPSS 16.0软件包进行独立样本t检验。结果:SM-AP1、SM-AP4细胞中均存在HER2蛋白表达及HER2基因扩增,应用HER2靶向抑制剂可以显著降低肿瘤细胞的增殖能力,阻滞细胞周期进程,诱导肿瘤细胞凋亡,并且HER2下游PI3K/Akt和MAPK/ERK细胞通路受到抑制。结论:MPA肿瘤细胞系中存在HER2基因过表达及扩增,HER2在MPA恶性生物学行为中扮演重要角色。抑制HER2,可以改善MPA的恶性生物学行为。

关键词: HER2, 恶性多形性腺瘤, 唾液腺

Abstract: PURPOSE:To inhibit HER2 in salivary malignant pleomorphic adenoma, investigate the effect on tumor cell proliferation, cell cycle and apoptosis, and assess the possibility of blocking HER2 to improve MPA malignant biological behavior. METHODS: HER2 expression and proliferation were detected in MPA cell lines. The effect on tumor cell proliferation, cell cycle, apoptosis and down-stream pathway were verified after use of HER2 blockade. SPSS 16.0 software package was used for statistical analysis. RESULTS: HER2 overexpressed/proliferated in SM-AP1 and SM-AP4 cells. By blocking HER2, tumor proliferation and cell cycle were significantly induced, and apoptosis process was activated. In addition, the downstream pathway PI3K/Akt and MAPK/ERK were significantly inhibited. CONCLUSIONS: HER2 overexpressed/proliferated in MPA cell line, which might play an important role in tumor genesis. Inhibiting HER2 might be a novel therapy for poor biological behavior on MPA.

Key words: HER2, Malignant pleomorphic tumor, Salivary gland

中图分类号:

R739.8

夏亮, 汪洋, 胡宇华, 王丽珍, 顾挺, 李江, 田臻. HER2基因在唾液腺恶性多形性腺瘤细胞增殖、周期、凋亡中的作用[J]. 中国口腔颌面外科杂志, 2018, 16(4): 310-316.

XIA Liang, WANG Yang, HU Yu-hua, WANG Li-zhen, GU Ting, LI Jiang, TIAN Zhen. Effect of HER2 gene on cell proliferation, cell cycle and apoptosis in salivary malignant pleomorphic adenoma[J]. China J Oral Maxillofac Surg, 2018, 16(4): 310-316.

参考文献

[1] Hashimoto K, Yamamoto H, Shiratsuchi H, et al.HER-2/neu gene amplification in carcinoma ex pleomorphic adenoma in relation to progression and prognosis: a chromogenic in situ hybridization study[J]. Histopathology, 2012, 60(6B): E131-142.
[2] Tian Z, Li L, Wang L, et al.Salivary gland neoplasms in oral and maxillofacial regions: a 23-year retrospective study of 6982 cases in an eastern Chinese population[J]. Int J Oral Maxillofac Surg, 2010, 39(3): 235-242.
[3] Marx AH, Tharun L, Muth J, et al.HER-2 amplification is highly homogenous in gastric cancer[J]. Hum Pathol, 2009, 40(6): 769-777.
[4] Glisson B, Colevas AD, Haddad R, et al.HER2 expression in salivary gland carcinomas: dependence on histological subtype[J]. Clin Cancer Res, 2004, 10(3): 944-946.
[5] Xia L, Hu Y, Li J, et al.A low percentage of HER-2 amplification whereas indicates poor prognosis in salivary carcinoma ex pleomorphic adenoma: a study of 140 cases[J]. J Oral Pathol Med, 2017, 46(3): 167-174.
[6] Molina MA, Saez R, Ramsey EE, et al.NH₂-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer[J]. Clin Cancer Res, 2002, 8(2): 347-353.
[7] Tevaarwerk AJ, Kolesar JM.Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer[J]. Clin Ther, 2009, 31(Pt 2): 2332-2348.
[8] Maruyama S, Cheng J, Shingaki S, et al.Establishment and characterization of pleomorphic adenoma cell systems: an in-vitro demonstration of carcinomas arising secondarily from adenomas in the salivary gland[J]. BMC Cancer, 2009, 9(2): 247.
[9] Wolff AC, Hammond ME, Hicks DG, et al.Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update[J]. Arch Pathol Lab Med, 2014, 138(2): 241-256.
[10] Shih J, Bashir B, Gustafson KS, et al.Cancer signature investigation: ERBB2 (HER2)-activating mutation and amplification-positive breast carcinoma mimicking lung primary[J]. J Natl Compr Canc Netw, 2015, 13(8): 947-952.
[11] Ulas A, Kos T, Avci N, et al.Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival[J]. Asian Pac J Cancer Prev, 2015, 16(4): 1643-1649.
[12] Longva KE, Pedersen NM, Haslekås C, et al.Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2[J]. Int J Cancer, 2005, 116(3): 359-367.
[13] Sakai K, Yokote H, Murakami-Murofushi K, et al.Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway[J]. Cancer Sci, 2007, 98(9): 1498-1503.
[14] Zhou X, Tan M, Stone Hawthorne V, et al.Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers[J]. Clin Cancer Res, 2004, 10(20): 6779-6788.
[15] Ohtsuka T, Sakaguchi M, Yamamoto H, et al.Interaction of cytokeratin 19 head domain and HER2 in the cytoplasm leads to activation of HER2-Erk pathway[J]. Sci Rep, 2016, 6: 39557.
[16] Burris HA 3rd. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib[J]. Oncologist, 2004, 9(Suppl 3): 10-15.
[17] 马传栋. 拉帕替尼联合硼替佐米抑制乳腺癌细胞生长及硼替佐米对拉帕替尼耐药细胞的活性的研究 [D]. 上海: 复旦大学, 2009.

HER2基因在唾液腺恶性多形性腺瘤细胞增殖、周期、凋亡中的作用

Effect of HER2 gene on cell proliferation, cell cycle and apoptosis in salivary malignant pleomorphic adenoma

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	韩林孜, 房义康, 禹雯怡, 王奇民, 童磊, 邱建忠, 袁荣涛. 口腔乳头状唾液腺瘤1例临床病理分析[J]. 中国口腔颌面外科杂志, 2022, 20(1): 98-100.
[2]	高倩倩, 尚伟, 刘晓华. 颊部小唾液腺黏液囊肿误诊1例报告[J]. 中国口腔颌面外科杂志, 2021, 19(1): 91-93.
[3]	张卓宇, 撒国良, 魏泽全, 杨学文. 唾液腺:新型冠状病毒的“蓄水池”和“受累者”[J]. 中国口腔颌面外科杂志, 2020, 18(6): 486-489.
[4]	王少如, 高健刚, 徐竹青, 陈正岗, 郑建金, 邱建忠, 袁荣涛, 周建华. 精囊内镜用于诊断和治疗11例阻塞性唾液腺疾病的效果评价[J]. 中国口腔颌面外科杂志, 2020, 18(6): 544-547.
[5]	沈逸超, 俞创奇, 王知俊, 张蔚蒨. 超声弹性成像在唾液腺非肿瘤疾病中的应用进展[J]. 中国口腔颌面外科杂志, 2020, 18(2): 177-181.
[6]	汪洋, 夏亮, 胡宇华, 张春叶, 王丽珍, 李江, 田臻. 基于RNA-Seq分析挖掘唾液腺多形性腺瘤核心基因及通路[J]. 中国口腔颌面外科杂志, 2019, 17(5): 397-402.
[7]	徐万林, 朱云, 卢浩, 刘丽敏, 沈淑坤, 刘胜文, 杨雯君. 15例下颌下腺复发性多形性腺瘤临床病理分析[J]. 中国口腔颌面外科杂志, 2019, 17(5): 465-468.
[8]	徐博雅, 杨子桧, 王珺, 雷德林, 杨新杰. CCL2和CCR2在唾液腺腺样囊性癌中的表达及意义[J]. 中国口腔颌面外科杂志, 2019, 17(4): 311-315.
[9]	王知俊，张蔚蒨，郑凌艳，曹宁宁，石欢，谢李松，俞创奇. 超声弹性成像技术在IgG4相关唾液腺炎诊断和随访中的应用[J]. 中国口腔颌面外科杂志, 2019, 17(3): 225-229.
[10]	傅锦业, 吴春晓, 沈淑坤, 郑莹, 张陈平, 张志愿. 2002—2013年上海市唾液腺恶性肿瘤流行情况分析[J]. 中国口腔颌面外科杂志, 2019, 17(2): 134-140.
[11]	汪洋, 田臻. 唾液腺黏液表皮样癌预后评估的组织病理学与分子病理指标[J]. 中国口腔颌面外科杂志, 2018, 16(4): 376-381.
[12]	李欢, 杨新杰, 王维戚, 雷德林. 应用RNA-Seq技术筛选唾液腺腺样囊性癌嗜神经侵袭相关差异表达基因[J]. 中国口腔颌面外科杂志, 2018, 16(2): 114-119.
[13]	夏亮, 胡宇华, 王丽珍, 顾挺, 李江, 田臻. 唾液腺恶性多形性腺瘤中CDH1基因启动子甲基化与E-cadherin表达的相关性分析[J]. 中国口腔颌面外科杂志, 2018, 16(2): 120-125.
[14]	王超, 黎婷, 严斐, 蔡文燕, 蒋星宇, 孙晋虎. 辛伐他汀联合干扰miR-21对唾液腺腺样囊性癌细胞迁移和侵袭的影响[J]. 中国口腔颌面外科杂志, 2018, 16(2): 132-137.
[15]	夏亮, 汪洋, 胡宇华, 顾挺, 李江, 石慧敏, 田臻. 唾液腺恶性多形性腺瘤HER2基因扩增与临床病理特征及预后的关系[J]. 中国口腔颌面外科杂志, 2018, 16(1): 12-19.